Healthcare -
Biotechnology - NASDAQ - US
$ 7.88
-4.02 %
$ 546 M
Market Cap
-11.59
P/E
1. INTRINSIC VALUE
Balance Sheet
Regulus Therapeutics Inc.
| Current Assets | 82.3 M |
| Cash & Short-Term Investments | 75.8 M |
| Receivables | 0 |
| Other Current Assets | 6.57 M |
| Non-Current Assets | 1.84 M |
| Long-Term Investments | 0 |
| PP&E | 1.81 M |
| Other Non-Current Assets | 25 K |
| Current Liabilities | 7.5 M |
| Accounts Payable | 947 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 6.55 M |
| Non-Current Liabilities | 274 K |
| Long-Term Debt | 274 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Regulus Therapeutics Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 50 M |
| Operating Income | -50 M |
| Other Expenses | -3.68 M |
| Net Income | -46.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Regulus Therapeutics Inc.
| Net Income | -46.4 M |
| Depreciation & Amortization | -1.21 M |
| Capital Expenditures | -340 K |
| Stock-Based Compensation | 7.74 M |
| Change in Working Capital | -1.88 M |
| Others | -2.62 M |
| Free Cash Flow | -42 M |
Wall Street Analysts Price Targets
Regulus Therapeutics Inc.
Wall Street analysts predict an average 1-year price target for RGLS of $7 , with forecasts ranging from
a
low of
$7 to a high of $7 .
RGLS Lowest Price Target
Wall Street Target
7 USD
-11.17%
RGLS Average Price Target
Wall Street Target
7 USD
-11.17%
RGLS Highest Price Target
Wall Street Target
7 USD
-11.17%
4. DIVIDEND
ANALYSIS
RGLS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Regulus Therapeutics Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
311 K USD 4
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
95.9 K USD 1
0-3 MONTHS
75 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
7.28 K USD 1
9-12 MONTHS
7. News
Novartis announces commencement of tender offer to acquire Regulus Therapeutics
Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc., a Delaware corporation (“Regulus”), in exchange for (i) $7.00 in cash per Share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone. Such offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase, dated May 27, 2025, and the related Letter of Transmittal (together, the “Offer”) and pursuant to the terms of the previously announced Agreement and Plan of Merger, dated as of April 29, 2025 (the “Merger Agreement”), among Novartis, Purchaser and Regulus.
globenewswire.com
- 3 weeks ago
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates
Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right ("CVR") upon the achievement of a regulatory milestone, for a total equity value of up to approximately $1.7 billion; Expected to be completed in the second half of 2025, subject to customary closing conditions Positive topline data from the completed fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) study of farabursen (RGLS8429) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Company on track for initiation of Phase 3 single pivotal trial in the third quarter 2025 SAN DIEGO , May 8, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We recently announced that we have entered into an agreement to be acquired by Novartis, whose established global development and commercial capabilities will potentially bring farabursen to patients with ADPKD, who currently have limited treatment options," said Jay Hagan, CEO of Regulus Therapeutics.
prnewswire.com
- 1 month ago
REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Regulus Therapeutics Inc. (NasdaqCM: RGLS) to Novartis AG. Under the terms of the proposed transaction, shareholders of Regulus will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect.
businesswire.com
- 1 month ago
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
NEW YORK , April 30, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Regulus Therapeutics Inc. (NASDAQ: RGLS ), relating to the proposed merger with Novartis AG.
prnewswire.com
- 1 month ago
Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday.
benzinga.com
- 1 month ago
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
benzinga.com
- 1 month ago
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus shareholders. Under the terms of the proposed transaction, Regulus shareholders will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus' lead product candidate.
businesswire.com
- 1 month ago
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Regulus will receive only $7.00 per share in cash at closing, or $0.8 billion. In addition.
businesswire.com
- 1 month ago
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
reuters.com
- 1 month ago
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The agreed deal is fully in line with the therapeutic area focus of Novartis and leverages our strength and expertise in renal disease.
globenewswire.com
- 1 month ago
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion Transaction is expected to be completed in the second half of 2025, subject to customary closing conditions SAN DIEGO , April 30, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will acquire Regulus for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. The upfront cash portion of the consideration represents a premium of 274 percent to Regulus' 60-day volume-weighted average stock price and 108 percent to Regulus' closing price on April 29, 2025.
prnewswire.com
- 1 month ago
Should You Buy Regulus (RGLS) After Golden Cross?
Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
zacks.com
- 1 month ago
8. Profile
Summary
Regulus Therapeutics Inc. RGLS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 546 M
Dividend Yield
0.00%
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Contact
4224 Campus Point Court, San Diego, CA, 92121
https://www.regulusrx.com
IPO
Date
Oct. 9, 2012
Employees
34
Officers
Dr. Rekha Garg M.D., M.S.
Chief Medical Officer
Dr. Claire Susan Padgett M.S., M.T., Ph.D.
Senior Vice President of Clinical Operations
Mr. Daniel J. Penksa
Vice President of Finance & Controller
Ms. Crispina Calsada CPA
Chief Financial Officer
Mr. Edmund Lee Ph.D.
Vice President of Translational Medicine
Mr. Christopher Ray Aker J.D.
Senior Vice President, General Counsel & Corporate Secretary
Mr. Joseph P. Hagan M.B.A.
Chief Executive Officer & Director
Dr. Preston S. Klassen M.D., M.H.S.
President, Head of Research & Development and Director